Maze Therapeutics (MAZE) had its price target raised by Wedbush from $43.00 to $58.00. They now have an "outperform" rating on the stock.
Maze Therapeutics (MAZE) was upgraded by Mizuho to "strong-buy".
Maze Therapeutics (MAZE) is now covered by Mizuho. They set an "outperform" rating and a $97.00 price target on the stock.
Maze Therapeutics (MAZE) had its "buy" rating reaffirmed by BTIG Research. They now have a $46.00 price target on the stock.
Maze Therapeutics (MAZE) had its price target raised by Guggenheim from $46.00 to $58.00. They now have a "buy" rating on the stock.